Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29686091 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CYP3A4CYP19A1LMNAKMT2A | |
| SCHEMBL30936872 | 0.89 | CYP19A1 (0.37) | ALDH1A1CYP3A4CYP19A1LMNAKMT2A | |
| SCHEMBL30936865 | 0.89 | CYP19A1 (0.37) | ALDH1A1CYP3A4CYP19A1LMNAKMT2A | |
| SCHEMBL26906921 | 0.87 | ALDH1A1 (0.44) | ALDH1A1CYP3A4CYP19A1LMNAKMT2A | |
| SCHEMBL29686620 | 0.83 | KMT2A (0.47) | ALDH1A1CYP3A4CYP19A1LMNAKMT2A | |
| SCHEMBL24498465 | 0.83 | KMT2A (0.47) | ALDH1A1CYP3A4CYP19A1LMNAKMT2A | |
| SCHEMBL24498481 | 0.83 | CYP19A1 (0.49) | ALDH1A1CYP19A1LMNAKMT2AMAPT | |
| SCHEMBL24497695 | 0.81 | CYP2C9 (0.50) | ALDH1A1CYP19A1LMNAKMT2AAPLNR | |
| SCHEMBL26512973 | 0.81 | LMNA (0.42) | ALDH1A1CYP19A1LMNAKMT2AMAPT | |
| SCHEMBL24498442 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CYP3A4KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024094171-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2024-05-10 | — | — | WO | disclosed |
| US-20240101548-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-4257587-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-4257587-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. | 2023-05-25 | — | — | US | disclosed |
| CN-114901656-B | Hydroximic acid ester compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-114901656-A | Hydroximic acid ester compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021216440-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101548-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TYK2, WEE2, WEE1 | ALDH1A1 3779/4885CYP3A4 3656/4885CYP19A1 1198/4885 |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | ERBB2, ALK, ERBB3 | ALDH1A1 4050/4885CYP3A4 4830/4885CYP19A1 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.